Abstract: An aged skin equivalent comprising an epidermis equivalent and an aged dermis equivalent, wherein the aged dermis equivalent comprises glycated collagen. An aged dermis equivalent, the epidermis equivalent obtained and methods of producing the aged skin and/or aged dermis equivalent and/or the epidermis equivalent.

Abstract: An aged skin equivalent comprising an epidermis equivalent and an aged dermis equivalent, wherein the aged dermis equivalent comprises glycated collagen.

Abstract: An aged skin equivalent comprising an epidermis equivalent and an aged dermis equivalent, wherein the aged dermis equivalent comprises glycated collagen. An aged dermis equivalent, the epidermis equivalent obtained and methods of producing the aged skin and/or aged dermis equivalent and/or the epidermis equivalent.

Abstract: An aged skin equivalent comprising an epidermis equivalent and an aged dermis equivalent, wherein the aged dermis equivalent comprises glycated collagen. An aged dermis equivalent, the epidermis equivalent obtained and methods of producing the aged skin and/or aged dermis equivalent and/or the epidermis equivalent.

Abstract: An aged skin equivalent comprising an epidermis equivalent and an aged dermis equivalent, wherein the aged dermis equivalent comprises glycated collagen.

Abstract: Topically applicable dermocosmetic compositions for improving or maintaining the appearance of human skin or the scalp, comprise a minor antioxidant effective amount of melatonin or analog thereof, formulated into a topically applicable, cosmetically/dermatologically acceptable vehicle, diluent or carrier therefor, such minor antioxidant effective amount being less than 10.sup.-4 % by weight relative to the total weight thereof, e.g., no greater than 0.5.times.10.sup.-4 % or ranging from 10.sup.-12 % to 10.sup.-15 % by weight thereof.

Abstract: Process for the preparation of fluoridated casein micelles, in which at least 100 ppm of a soluble fluoride salt are added of a solution comprising micellar casein and the fluoridated micellar casein is isolated. Food or pharmaceutical composition for treating dental caries or plaque comprising an effective quantity of fluoridated micellar casein or its micellar subunits.

Abstract: The present invention relates to compositions and methods for increasing the alertness of an individual through the administration of a stimulant such as xanthine or an xanthine derivative and preferably caffeine. A particular composition has one or more layers containing the stimulant arranged about the cores of microparticles. This allows the composition to release a significant portion of the stimulant within about two hours after administration so that a level of alertness can be readily achieved. Thereafter, the balance of the composition is released within about 6 to 10 hours, so that the stimulant can provide alertness during that time, but then can dissipate to levels which would not affect the individual's ability to sleep. Also, the formulation is carefully designed so that the stimulant does not accumulate in the individual's system.

Abstract: The present invention relates to compositions and methods for increasing the alertness of an individual through the administration of a stimulant such as xanthine or an xanthine derivative and preferably caffeine. A particular composition has one or more layers containing the stimulant arranged about the cores of microparticles. This allows the composition to release a significant portion of the stimulant within about two hours after administration so that a level of alertness can be readily achieved. Thereafter, the balance of the composition is released within about 6 to 10 hours, so that the stimulant can provide alertness during that time, but then can dissipate to levels which would not affect the individual's ability to sleep. Also, the formulation is carefully designed so that the stimulant does not accumulate in the individual's system.

Abstract: A pharmaceutical delivery system includes a dispenser pack containing a pharmaceutical composition. The composition includes a pharmaceutical active principle homogeneously distributed in a water-dispersible gel excipient containing an acrylamide or acrylamidine gelling agent.

Abstract: A pharmaceutical active principle delivery system has a pharmaceutical active principle contained in solution or solid form in an excipient gel formed with gelling agents which provide for a pseudoplastic and more or less thixotropic water-dispersible gel which may be packed in a dispenser having a metering pump for delivering therapeutic doses of the composition.